Biochemical Impact and Therapeutic Efficacy of Laparoscopic Surgery in Early-Stage Ovarian Cancer: Modulation of Vascular Endothelial Growth Factor and Tumor Markers

Biochemical Outcomes of Laparoscopic Surgery in Early Ovarian Cancer

  • Peng Han The second Affiliated Hospital of Xingtai Medical College
  • Yafei Liu The second Affiliated Hospital of Xingtai Medical College
  • Jin Han The First Affiliated Hospital of Xingtai Medical College
DOI: https://doi.org/10.5937/jomb0-56011
Keywords: Laparoscopic surgery, open surgery, early ovarian cancer, vascular endothelial growth factor, tumor markers, angiogenesis, biochemical markers, enzyme-linked immunosorbent assay.

Abstract


Background: The objective of this study was to investigate the biochemical impact of laparoscopic surgery on angiogenesis, focusing on vascular endothelial growth factor (VEGF), and the modulation of key tumor markers in patients with early-stage ovarian cancer.

Methods: A total of 76 patients diagnosed with early ovarian cancer were enrolled and divided into two groups based on the surgical approach: the control group (n=38) underwent open surgery, and the observation group (n=38) underwent laparoscopic surgery. Surgical parameters, VEGF levels, tumor markers [matrix metalloproteinase 9 (MMP9), stromal cell-derived factor-1α (SDF-1α), and carcinoembryonic antigen (CEA)], survival rates, and incidence of complications were compared between the two groups.

Results: The duration of surgery was longer in the observation group than in the control group. However, the hospitalization time, recovery of bowel function, and length of surgical incision were significantly shorter in the observation group. Intraoperative blood loss was also significantly lower in the observation group, with all differences being statistically significant (P<0.01). Seven days post-surgery, VEGF, MMP9, SDF-1α, and CEA levels in both groups decreased compared to their preoperative levels. These levels were significantly lower in the observation group than in the control group (P<0.05). The 24-month survival rate was higher in the observation group (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups (P>0.05).

Conclusion: Laparoscopic surgery for early ovarian cancer results in minimal trauma, reduces VEGF and tumor marker levels, and improves the 24-month survival rate without increasing the incidence of complications.

References

1. Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer 2023; 4(9): 1239-57.
2. Stone R, Sakran JV, Long RK. Salpingectomy in Ovarian Cancer Prevention. Jama-J Am Med Assoc 2023; 329(23): 2015-6.
3. Dai W, Zhou J, Chen T. Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance. Mol Cancer 2024; 23(1): 201.
4. Hieromnimon HM, Pearson AT. Ovarian cancer through a multi-modal lens. Nat Cancer 2022; 3(6): 662-4.
5. Coleman RL. For ovarian cancer PARPi maintenance therapy: more is better, right? Ann Oncol 2022; 33(6): 569-70.
6. Smith A, Howell EA, Ko EM. Ovarian Cancer Isn't Just a White Woman's Disease. Jama Oncol 2024; 10(6): 697-8.
7. Wise J. Ovarian cancer: NICE recommends expanding availability of genetic testing. Bmj-Brit Med J 2023; 382: 2111.
8. Moore KN, du Bois A. Homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol 2022; 33(3): 231-3.
9. Gu Y, Zhang L, Lv W. Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer. Signal Transduct Tar 2024; 9(1): 260.
10. Fillon M. Opportunistic salpingectomy may reduce ovarian cancer risk. Ca-Cancer J Clin 2022; 72(2): 97-9.
11. Tissue-Resident Memory-like Lymphocytes Demonstrate Effector Activity in Ovarian Cancer. Cancer Discov 2022; 12(6): OF11.
12. Gallotta V, Certelli C, Oliva R, Rosati A, Federico A, Loverro M, et al. Robotic surgery in ovarian cancer. Best Pract Res Cl Ob 2023; 90: 102391.
13. Cromi A, Bogani G, Uccella S, Casarin J, Serati M, Ghezzi F. Laparoscopic fertility-sparing surgery for early stage ovarian cancer: a single-centre case series and systematic literature review. J Ovarian Res 2014; 7: 59.
14. Lu Y, Yao DS, Xu JH. Systematic review of laparoscopic comprehensive staging surgery in early stage ovarian cancer: a meta-analysis. Taiwan J Obstet Gyne 2015; 54(1): 29-38.
15. Jochum F, Aubry G, Pellerin M, Billard C, Faller E, Boisrame T, et al. Relevance of Laparoscopic Surgery for Ovarian Cancer in Well-selected Patients: A Propensity-matched Comparison With Laparotomy. Anticancer Res 2021; 41(2): 955-65.
16. He Y, OuYang Z, Liu W, Chen Y, Zhang Q. TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing. Oncogene 2023; 42(1): 49-61.
17. Murphy AD, Morgan RD, Clamp AR, Jayson GC. The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. Brit J Cancer 2022; 126(6): 851-64.
18. Pawar NR, Buzza MS, Duru N, Strong AA, Antalis TM. Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis. J Cell Biol 2023; 222(11):
19. Wu Z, Jia Q, Liu B, Fang L, Leung P, Cheng JC. NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling. Exp Cell Res 2023; 430(1): 113693.
20. Dai JM, Sun K, Li C, Cheng M, Guan JH, Yang LN, et al. Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1alpha. Clin Transl Oncol 2023; 25(6): 1606-16.
21. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. Bmj-Brit Med J 2020; 371: m3773.
22. Ronsini C, Pasanisi F, Molitierno R, Iavarone I, Vastarella MG, De Franciscis P, et al. Minimally Invasive Staging of Early-Stage Epithelial Ovarian Cancer versus Open Surgery in Terms of Feasibility and Safety: A Systematic Review and Meta-Analysis. J Clin Med 2023; 12(11):
23. Yin S, Gao W, Shi P, Xi M, Tang W, Zhang J. Primary Laparoscopic Surgery Does Not Affect the Prognosis of Early-Stage Ovarian Clear Cell Cancer. Cancer Manag Res 2021; 13: 6403-9.
Published
2025/02/16
Issue
Vol. 44 No. 3 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Peng Han, Yafei Liu, Jin Han

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.